Oncoinvent ASA: Minutes from Annual General Meeting

20 May 2026 11:15 CEST

20 May 2026, Oslo Norway: The Annual general meeting of the Company was held
today, 20 May 2026, by electronic means through Lumi AGM. All proposals on the
agenda were adopted in accordance with the proposals set out in the notice dated
28 April 2026.

The complete minutes of the ordinary general meeting are attached to this
release and are also available on the Company's website,
https://www.oncoinvent.com/investors/general
-meetings/. (https://www.oncoinvent.com/investors/general-meetings/)

Oncoinvent ASA - Minutes of Annual General Meeting 20 May
2026 (https://mb.cision.com/Public/15728/4350758/8306b30462b1fc8e.pdf)

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com (soug@oncoinvent.com)

This information is subject to the disclosure requirements pursuant to Euronext
Oslo Rule Book II for companies listed on Oslo Børs and Section 5-12 of the
Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation
therapy that leverages the unique anatomy of the abdominal cavity to destroy
residual micrometastases using a single, highly localized dose of alpha
radiation. The initial clinical focus is treatment of ovarian and colorectal
cancer patients after surgical removal of the primary tumor and visible
metastases in the peritoneum, the thin membrane lining the abdominal cavity and
covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the
peritoneal cavity, keeping patients disease-free for longer than the current
standard of care and thereby also impacting overall survival. It is broadly
applicable to any cancer that spreads to the peritoneum, e.g. ovarian,
colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity,
excellent safety profile, and seamless integration into existing surgical
workflows. Oncoinvent's product is easy to use, avoids systemic delivery and
significant toxicity. It is also differentiated in being simple to manufacture,
scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers,
are highly promising, showing an excellent safety profile and meaningful signals
of efficacy. Interim data from an ongoing, randomized, controlled phase 2
ovarian cancer trial is expected in 2026. With cost-effective manufacturing,
blockbuster potential, active pharma partnership momentum, plus strong
endorsements from leading experts, Oncoinvent is built for scale and commercial
success, and is set to become the new standard for post-surgical cancer care.
The Company was founded by the originators of Algeta and Xofigo (acquired by
Bayer).

More information:
Access the news on Oslo Bors NewsWeb site

673953_Oncoinvent_ASA_Minutes_of_Annual_General_Meeting_20_May_2026_signed.pdf